Enanta Pharmaceuticals, Inc.

US$11.00As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:ENTAHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR (7.30%)
Div yield —
ROE (70.12%)
Biotechnology
Beta (5Y) 0.76
PE TTM —
TSR TTM 0.36%
Mkt cap US$320.4M
ROIC (50.40%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$14
28.04%
(59.12%)
Hold 2|2|9|6|1
1Q26
2Q26
3Q26
4Q26
Earnings per share$
0.17
0.18
0.20
0.21
7.25%
8.15%
17.97%
28.86%
Revenue$M
16.16
15.88
16.43
16.61
(1.69%)
(7.63%)
(1.91%)
1.87%
Peers (US$320.4M)
Cap (US$)
PE
323.5M
16.63x
Capital
TTM
5Y
10Y
Leveragex
0.609
—
—
EBIT/Intx
1.039
0.154
0.153
Own earn%
172.09
(163.60)
(160.17)
Sh yield%
27.21
37.13
35.50
Owners
Insiders/Inst%
6.97
30.66
Short interest%
1.62
SBC / revenue%
4.17
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
2
Op margin range%
16–25
$1 testx
—
Incr. ROIC%
28